Summary
This PREDICT1 observational study developed a blood proteomic classifier using mass spectrometry to identify non-squamous NSCLC patients likely to benefit from carboplatin and pemetrexed chemotherapy. In a validation cohort (n=94), the classifier successfully stratified patients into good and poor responder groups, with the good responder group demonstrating significantly higher objective response rates (30.9% vs 5.1%), median progression-free survival (6.0 vs 2.3 months), and median overall survival (25.7 vs 5.1 months). These findings suggest that pre-treatment blood proteomic profiling may help optimise treatment selection in advanced NSCLC.
UK applicability
This biomarker discovery study has potential relevance to UK oncology practice if the proteomic classifier is validated in prospective trials and becomes clinically available; however, the findings are specific to a Japanese patient cohort and would require validation in UK and European populations before implementation in NHS cancer services.
Key measures
Objective response rate (RECIST v1.1), progression-free survival (median and hazard ratio), overall survival (median and hazard ratio), protein expression profiles via mass spectrometry
Outcomes reported
The study developed and validated a proteomic classifier using mass spectrometry analysis of pre-treatment blood samples to predict clinical benefit from carboplatin and pemetrexed chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer. Primary outcomes measured were objective response rate, progression-free survival, and overall survival stratified by classifier prediction.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.